Literature DB >> 26560170

Tazarotene foam, 0.1%, for the treatment of acne.

Jaclyn A Smith1, Swetha Narahari2, Dane Hill3, Steven R Feldman4.   

Abstract

INTRODUCTION: Acne is a common skin condition of the pilosebaceous units that affects the young and old, ranges from moderate to severe and can be treated with an array of options. Topical retinoids are the initial treatment for acne due to their ability to treat comedones, the starting point of acne. AREAS COVERED: Tazarotene is a topical retinoid available as a cream, gel and foam. Tazarotene 0.1% foam was FDA approved in 2012 for the treatment of acne in patients ages ≥12 and is the first foam topical retinoid on the market. Phase I and III trials support the efficacy and safety of tazarotene foam for acne. EXPERT OPINION: The foam vehicles may increase compliance and satisfaction in some patients and as retinoids are commonly first line acne treatments, this new topical retinoid foam may be a useful option for some acne patients.

Entities:  

Keywords:  adherence; efficacy; retinoid; topical

Mesh:

Substances:

Year:  2015        PMID: 26560170     DOI: 10.1517/14740338.2016.1117605

Source DB:  PubMed          Journal:  Expert Opin Drug Saf        ISSN: 1474-0338            Impact factor:   4.250


  4 in total

1.  Bioavailability, Pharmacokinetics, and Transepidermal Water Loss of Short Contact Tazarotene Lotion 0.1% Versus Tazarotene (Tazorac®) Cream 0.1.

Authors:  Srinivas Sidgiddi; Kent Allenby; Franklin Okumu; Anirudh Gautam
Journal:  J Clin Aesthet Dermatol       Date:  2019-09-01

2.  Tazarotene 0.045% Lotion for Moderate-to-Severe Acne in Male and Female Participants: A Phase II Post-hoc Analysis.

Authors:  Hilary E Baldwin; Lawrence J Green; Leon Kircik; Eric Pierre Guenin; Anya Loncaric Forest; Radhakrishnan Pillai
Journal:  J Clin Aesthet Dermatol       Date:  2021-04-01

Review 3.  Targeted Topical Delivery of Retinoids in the Management of Acne Vulgaris: Current Formulations and Novel Delivery Systems.

Authors:  Gemma Latter; Jeffrey E Grice; Yousuf Mohammed; Michael S Roberts; Heather A E Benson
Journal:  Pharmaceutics       Date:  2019-09-24       Impact factor: 6.321

4.  Topical Tazarotene Gel, 0.1%, as a Novel Treatment Approach for Atrophic Postacne Scars: A Randomized Active-Controlled Clinical Trial.

Authors:  T P Afra; Muhammed Razmi T; Tarun Narang; Sunil Dogra; Ashok Kumar
Journal:  JAMA Facial Plast Surg       Date:  2019-03-01       Impact factor: 4.611

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.